Board of Directors

Board of Directors
Home / About Protalix / Board of Directors

Board of Directors

Shlomo Yanai

Chairman
-more-

Shlomo Yanai has served as the Chairman of our Board of Directors since July 2014.  Mr. Yanai is currently the Chairman of the Board of Cambrex Corporation and a director of Quinpario Acquisition Corp. 2.  Mr. Yanai served as a director of Lumenis Ltd. from 2012 through 2015; of Sagent Pharmaceuticals, Inc. from April 2015 through August 2016; and of Perrigo Co. plc from November 2015 through January 2017.   Mr. Yanai served as President and Chief Executive Officer of Teva Pharmaceutical Industries Ltd. from March 2007 until May 2012 and, prior to joining Teva, Mr. Yanai was President and Chief Executive Officer of Makhteshim-Agan Industries Ltd. from 2003 until 2006.  Before that, he was a Major General in the Israel Defense Forces, where he served for 32 years, in various positions, the last two positions being Commanding Officer of the Southern Command and Head of the Division of Strategic Planning.  Mr. Yanai was the head of the Israeli security delegation to the peace talks at Camp David, Shepherdstown and Wye River.  He currently serves as a member of the Board of Governors of the Technion — Israel Institute of Technology of Haifa, Israel, and of the Board of Trustees of Bar-Ilan University — Israel, as well as an honorary member of the Board of the Institute for Policy and Strategy of the Interdisciplinary Center (IDC), Herzliya, Israel.  Mr. Yanai holds a bachelor’s degree in political science and economics from Tel Aviv University, a master’s degree in national resources management from George Washington University, and is a graduate of the Advanced Management Program of Harvard Business School and U.S. National War College (NDU).  Mr. Yanai was the recipient of the Max Perlman Award for Excellence in Global Business Management from Tel Aviv University, Israel in 2005 and was awarded an honorary doctorate by Bar-Ilan University, Israel in 2012.

Moshe Manor

President & Chief Executive Officer, Director
-more-

Moshe Manor has served as our President and Chief Executive Officer and as a director of our company since November 2014. Prior to joining Protalix, Mr. Manor served in a number of senior executive positions at Teva Pharmaceutical Industries Ltd. from 1984 through 2012.  Most recently, he served as President, Teva Asia & Pacific where he led the strategy and development of a high growth region for Teva.  Prior to that, he was Group Vice President, Global Branded Products, leading the Innovative Commercial and Research & Development franchises.  From 2006 through 2008, Mr. Manor was Senior Vice President, Global Innovative Resources, and was responsible for generating over $3 billion in sales with Copaxone® and Azilect®.  Previously, he served as director of Teva Israel.  Most recently, Mr. Manor serves on the Board of Directors of Kamedis Ltd. and Coronis Partners, and as Chairman of the Board of Directors of a startup company, MEway Pharma.  He holds a BA in Economics from the Hebrew University in Jerusalem, and an M.B.A. from the Tel-Aviv University.

Zeev Bronfeld

Director
-more-

Zeev Bronfeld has served as a director of Protalix Ltd. since 1996 and as our director since December 2006.  Mr. Bronfeld brings to us vast experience in management and value building of biotechnology companies.  He is an experienced businessman who is involved in a number of biotechnology companies.  He was a co-founder of Biocell Ltd., a former Israeli publicly-traded holding company that specialized in biotechnology companies and served as its Chief Executive Officer from 1986 through 2015.  Mr. Bronfeld currently serves as a director of The Trendlines Group and D.N.A. Biomedical Solutions Ltd., both of which are public companies.  Mr. Bronfeld is also a director of a number of privately-held companies, most of which are involved in the life sciences, such as Entera Bio Ltd., Contipi Medical Ltd. and TransBiodiesel Ltd.  From 2008 through January 2017, Mr. Bronfeld served as a director of Macrocure Ltd., a Nasdaq-listed company that merged into Leap Therapeutics, Inc. (NASDAQ:LPTX), and from 2004 through 2012, Mr. Bronfeld served as a director of D. Medical Industries Ltd., a company that was dually-listed on the Nasdaq and the TASE.  Mr. Bronfeld received a B.A. in Economics from the Hebrew University in 1975. 

Yodfat Harel Buchris

Director
-more-

Yodfat Harel Buchris has served as our director since June 2007.  Since February 2014, Ms. Harel Buchris has served as the employer representative in Israel’s National Labor Court.  She is also a Partner and a member of the board of directors of YP and 6 Partners Ltd., a business consulting and investment company.  Since February 2016 she has served on the board of directors of Israel Discount Bank Limited and, since January 2016, on the board of directors of Eltek Ltd.  From 2006 to 2013, Ms. Harel Buchris served as a Managing Director of Tamares Capital Ltd., a private investment group with interests in real estate, technology, manufacturing, leisure and media.  At Tamares Capital, Ms. Harel Buchris served as the Business Development Director and the head of the Israel office.  Prior to joining Tamares Capital, from 2004 to 2006, she was the Head of the Medical Desk of Orbotech, Ltd., a company providing high-tech inspection and imaging solutions for bare printed circuit board (PCB), flat panel display (FPD) and PCB assembly manufacturing worldwide.  Prior to that, from 1994 to 2003, she was a Managing Director of Harel-Hertz Investment House Ltd., a business investment company with offices in Tel Aviv, Israel and Tokyo, Japan.  In 2002, Harel-Hertz Investment House became the Israeli representative office for ITX Corporation, a publicly-traded company in Japan.  Ms. Harel Buchris has served on the board of directors of Tamares Capital, Tamares Hotels, El Al, British Israel, Storewiz, N-trig, Secure Pharma, Siklu and Tamares Telecom.  Ms. Harel Buchris holds a B.A. in Communications and Political Science from Bar Ilan University and an executive M.B.A. from Bradford University, Great Britain.  She has also completed programs in Mediation at Gome, Israel Mediation Center, Directors’ Studies and Advanced Advertising and Marketing at the Israel Management Center.

Amos Bar Shalev

Director
-more-

Amos Bar Shalev has served as our director since July 2008.  Previously, Mr. Bar Shalev served as a director of Protalix Ltd. from 2005 through January 2008, and as our director from 2006 through 2008.  Mr. Bar Shalev brings to us extensive experience in managing technology companies.  Currently, Mr. Bar Shalev serves on the boards of directors of Aposense Ltd., an Israeli publicly-traded company listed on the TASE, since 2011, as well as Twine Solutions Ltd., a privately-held technology company, since 2015, and of Ocure Ltd., since 2012, both privately-held Israeli companies.  From 2004 through 2012, Mr. Bar Shalev served as a director of Technorov Holdings (1993) Ltd. and managed its portfolio.  In addition, he served on the board of directors of Highcon Systems Ltd., a privately-held Israeli company, from 2010 through 2012.  From 1997 through 2004, he was a Managing Director of TDA Capital Partners, a management company of the TGF (Templeton Tadiran) Fund.  From 2004 through 2007, he was the President of Win Buyer Ltd.  He has served on the board of directors of a number of Israeli publicly traded and privately-held Israeli companies including, among others, Velox Ltd., NESS Ltd. (acquired by BioNess Inc.), Idanit (acquired by Scitex Corporation Ltd.), Objet Geometrix (merged with Stratasys, Inc.), Verisity, Scitex Vision (acquired by Hewlett Packard), Golden Wings Investment Company Ltd., the venture capital fund of the Israeli Air Force Veterans Business Club, Win Buyer Ltd. and Sun Light Ltd.  He received his B.Sc. in Electrical Engineering from the Technion, Israel in 1978 and M.B.A. from the Tel Aviv University in 1981.  He holds the highest award from the Israeli Air Force for technological achievements.

Aharon Schwartz, PhD

Director
-more-

Aharon Schwartz, Ph.D. has served as our director since November 2014.  He retired from Teva in 2011 where he served in a number of positions from 1975 through 2011, the most recent being Vice President, Head of Teva Innovative Ventures from 2008.  Dr. Schwartz is currently chairman of the board of directors of a number of life science companies, including BiolineRx Ltd and CureTech Ltd., and a member of the board of directors of Alcobra Ltd. and Foamix Pharmaceuticals Ltd.  Dr. Schwartz received his Ph.D. in organic chemistry in 1978 from the Weizmann Institute of Science, his M.Sc. in organic chemistry from the Technion and a B.Sc. in chemistry and physics from the Hebrew University of Jerusalem.  Dr. Schwartz received a second Ph.D. in 2014 from the Hebrew University of Jerusalem in the history and philosophy of science.